Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia

G. Martorana, C. Giberti, F. Di Silverio, M. Von Heland, P. Rigatti, R. Colombo, G. Casadei, P. Pacifico

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the α1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). Material and Methods: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). Results and Conclusion: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalEuropean Urology
Volume32
Issue number1
Publication statusPublished - 1997

Fingerprint

Urodynamics
Prostatic Hyperplasia
Pressure
Placebos
Urethral Obstruction
Therapeutics
alfuzosin

Keywords

  • α-Antagonist
  • Alfuzosin
  • Benign prostatic hyperplasia
  • Urodynamics

ASJC Scopus subject areas

  • Urology

Cite this

Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. / Martorana, G.; Giberti, C.; Di Silverio, F.; Von Heland, M.; Rigatti, P.; Colombo, R.; Casadei, G.; Pacifico, P.

In: European Urology, Vol. 32, No. 1, 1997, p. 47-53.

Research output: Contribution to journalArticle

Martorana, G, Giberti, C, Di Silverio, F, Von Heland, M, Rigatti, P, Colombo, R, Casadei, G & Pacifico, P 1997, 'Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia', European Urology, vol. 32, no. 1, pp. 47-53.
Martorana, G. ; Giberti, C. ; Di Silverio, F. ; Von Heland, M. ; Rigatti, P. ; Colombo, R. ; Casadei, G. ; Pacifico, P. / Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. In: European Urology. 1997 ; Vol. 32, No. 1. pp. 47-53.
@article{3d94c89e0f234a4a80ee5c87202361ec,
title = "Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia",
abstract = "Objective: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the α1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). Material and Methods: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). Results and Conclusion: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0{\%}) and decreased detrusor pressure at maximum flow (-30.2{\%}), detrusor opening pressure (-39.4{\%}) and maximum detrusor pressure (-28.7{\%}). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.",
keywords = "α-Antagonist, Alfuzosin, Benign prostatic hyperplasia, Urodynamics",
author = "G. Martorana and C. Giberti and {Di Silverio}, F. and {Von Heland}, M. and P. Rigatti and R. Colombo and G. Casadei and P. Pacifico",
year = "1997",
language = "English",
volume = "32",
pages = "47--53",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia

AU - Martorana, G.

AU - Giberti, C.

AU - Di Silverio, F.

AU - Von Heland, M.

AU - Rigatti, P.

AU - Colombo, R.

AU - Casadei, G.

AU - Pacifico, P.

PY - 1997

Y1 - 1997

N2 - Objective: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the α1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). Material and Methods: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). Results and Conclusion: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

AB - Objective: The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the α1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH). Material and Methods: Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind). Results and Conclusion: Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.

KW - α-Antagonist

KW - Alfuzosin

KW - Benign prostatic hyperplasia

KW - Urodynamics

UR - http://www.scopus.com/inward/record.url?scp=0030758539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030758539&partnerID=8YFLogxK

M3 - Article

C2 - 9266231

AN - SCOPUS:0030758539

VL - 32

SP - 47

EP - 53

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -